Back to Browse Journals » International Journal of Nanomedicine » Volume 7
Delivery of a transforming growth factor β-1 plasmid to mesenchymal stem cells via cationized Pleurotus eryngii polysaccharide nanoparticles
Authors Deng WW, Cao X, Wang M, Qu R, Su WY, Yang Y, Wei YW, Xu XM, Yu JN
Received 7 November 2011
Accepted for publication 20 January 2012
Published 14 March 2012 Volume 2012:7 Pages 1297—1311
DOI https://doi.org/10.2147/IJN.S28010
Review by Single-blind
Peer reviewer comments 4
Wen Wen Deng*, Xia Cao*, Miao Wang*, Rui Qu, Wei Yan Su, Yan Yang, Ya Wei Wei, Xi Ming Xu, Jiang Nan Yu
Department of Pharmaceutics, School of Pharmacy and Center for Nano Drug/Gene Delivery and Tissue Engineering, Jiangsu University, Zhenjiang, People’s Republic of China
*These authors contributed equally to this work
Abstract: The objective of this study was to investigate the use of cationized Pleurotus eryngii polysaccharide (CPEPS) as a nonviral gene delivery vehicle to transfer plasmid DNA encoding transforming growth factor beta-1 (pTGF-β1) into mesenchymal stem cells (MSCs) in vitro. Crude P. eryngii polysaccharide was purified, and then cationized by grafting spermine onto the backbone of the polysaccharide. Agarose gel electrophoresis, transmission electron microscopy, and a Nano Sense Zetasizer (Malvern Instruments, Malvern, UK) were used to characterize the CPEPS-pTGF-β1 nanoparticles. The findings of cytotoxicity analysis showed that when the nanoparticles were formulated with a CPEPS/pTGF-β1 weight ratio ≥ 10:1, a greater gel retardation effect was observed during agarose gel electrophoresis. The CPEPS-pTGF-β1 nanoparticles with a weight ratio of 20:1, respectively, possessed an average particle size of 80.8 nm in diameter and a zeta potential of +17.4 ± 0.1 mV. Significantly, these CPEPS-pTGF-β1 nanoparticles showed lower cytotoxicity and higher transfection efficiency than both polyethylenimine (25 kDa) (P = 0.006, Student’s t-test) and LipofectamineTM 2000 (P = 0.002, Student’s
t-test). Additionally, the messenger RNA expression level of TGF-β1 in MSCs transfected with CPEPS-pTGF-β1 nanoparticles was significantly higher than that of free plasmid DNA-transfected MSCs and slightly elevated compared with that of Lipofectamine 2000-transfected MSCs. Flow cytometry analysis demonstrated that 92.38% of MSCs were arrested in the G1 phase after being transfected with CPEPS-pTGF-β1 nanoparticles, indicating a tendency toward differentiation. In summary, the findings of this study suggest that the CPEPS-pTGF-β1 nanoparticles prepared in this work exhibited excellent transfection efficiency and low toxicity. Therefore, they could be developed into a promising nonviral vector for gene delivery in vitro.
Keywords: nonviral gene vector, transfection, plasmid DNA, spermine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Other articles by this author:
Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug
Yi C, Zhong H, Tong S, Cao X, Firempong CK, Liu H, Fu M, Yang Y, Feng Y, Zhang H, Xu X, Yu J
International Journal of Nanomedicine 2012, 7:5067-5078
Published Date: 18 September 2012
In vitro release and in vitro–in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles
Cao X, Deng WW, Fu M, Wang L, Tong SS, Wei YW, Xu Y, Su WY, Xu XM, Yu JN
International Journal of Nanomedicine 2012, 7:753-762
Published Date: 14 February 2012
Encapsulation of plasmid DNA in calcium phosphate nanoparticles: stem cell uptake and gene transfer efficiency
Cao X, Deng W, Wei Y, Su W, Yang Y, Wei Y, Yu J, Xu X
International Journal of Nanomedicine 2011, 6:3335-3349
Published Date: 13 December 2011
Readers of this article also read:
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Clinical Interventions in Aging 2015, 10:1873-1879
Published Date: 19 November 2015
Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases
Tateiwa T, Takahashi Y, Ishida T, Kubo K, Masaoka T, Shishido T, Sano K, Yamamoto K
Therapeutics and Clinical Risk Management 2015, 11:1383-1389
Published Date: 15 September 2015
Emerging and future therapies for hemophilia
Carr ME, Tortella BJ
Journal of Blood Medicine 2015, 6:245-255
Published Date: 3 September 2015
Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
Cai Y, An SSA, Kim SY
Clinical Interventions in Aging 2015, 10:1163-1172
Published Date: 14 July 2015
Acquired hemophilia A: emerging treatment options
Janbain M, Leissinger CA, Kruse-Jarres R
Journal of Blood Medicine 2015, 6:143-150
Published Date: 8 May 2015
A new recombinant factor VIII: from genetics to clinical use
Santagostino E
Drug Design, Development and Therapy 2014, 8:2507-2515
Published Date: 12 December 2014
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A
Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S
Neuropsychiatric Disease and Treatment 2014, 10:865-867
Published Date: 16 May 2014
A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
Lentz SR, Tandra A, Gut RZ, Cooper DL
Journal of Blood Medicine 2014, 5:1-3
Published Date: 13 January 2014
Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy
Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS
International Journal of Nanomedicine 2012, 7:4077-4088
Published Date: 27 July 2012
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
International Journal of Nanomedicine 2010, 5:581-591
Published Date: 6 August 2010
